Esmya ® Prescription Patterns in Europe: A Retrospective Drug Utilization Chart Review Study

First published: 04/02/2015

Last updated: 25/06/2025





Administrative details

EU PAS number	
EUPAS8533	
Study ID	
8534	
DARWIN EU® study	
No	
Study countries	
France	
Germany	
Italy	
Spain	

Study status

Ongoing

Research institutions and networks

Institutions

inVentive Health

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Contact details

Study institution contact

Simeon Ocran simeon.ocran@preglem.com

Study contact

simeon.ocran@preglem.com

Primary lead investigator

Erwin Göckeler-Leopold

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 26/05/2014 Actual: 06/06/2014

Study start date

Planned: 30/05/2014 Actual: 12/11/2014

Date of interim report, if expected

Planned: 11/02/2015

Date of final study report

Planned: 31/12/2015

Sources of funding

• Pharmaceutical company and other private sector

More details on funding

PregLem SA

Study protocol

riskmgtsystem-pgl11020protocol.pdf (362.78 KB)

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study type:

Non-interventional study

Scope of the study:

Drug utilisation

Effectiveness study (incl. comparative)

Main study objective:

The aim of this drug utilization study is to provide real-world data related to the current prescription utilization patterns of Esmya ®.Study objectives are as follows:• To document Esmya ® utilization patterns in real medical practice.• To characterize the patients who are prescribed Esmya ® in real medical practice.• To characterize the profile of prescribers of Esmya.

Study drug and medical condition

Name of medicine

ESMYA

Population studied

Age groups

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Estimated number of subjects

1000

Study design details

Data analysis plan

• For the Interim Analysis, the Interim Study Group will include data from Cohort 1 (UK and Germany) • For the Final Analysis, the Final Study Group will include data from two cohorts, the Cohort 1 (UK and Germany) and the Cohort 2 (France, Italy and Spain). The number of patients in the Interim/Final Study Group and their associated characteristics will be described. The number of prescribers and their associated characteristics will also be described. Descriptive statistics will be used to summarize prescriber information and patient medical chart information. Summary statistics for continuous variables will include number of observations, mean, standard deviation, median, minimum, and maximum. Summary statistics for categorical data (dichotomous and polychotomous variables) will include counts and percentages. The 95% confidence intervals (95% CI) will be reported where appropriate. Country-specific analyses will be performed, where appropriate.

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

Other

Data sources (types), other

Prescription event monitoring

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No